ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -7 مورد

Oxazepam: Drug information

Oxazepam: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Oxazepam: Patient drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Risk from concomitant use with opioids:

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.

Abuse, misuse, and addiction:

The use of benzodiazepines, including oxazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing oxazepam and throughout treatment, assess each patient's risk for abuse, misuse, and addiction.

Dependence and withdrawal reactions:

The continued use of benzodiazepines, including oxazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of oxazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue oxazepam or reduce the dosage.

Brand Names: Canada
  • APO-Oxazepam;
  • DOM-Oxazepam;
  • PRO-Oxazepam;
  • RIVA-Oxazepam
Pharmacologic Category
  • Benzodiazepine
Dosing: Adult

Dosage guidance:

Safety: Reduce dose or avoid use in patients receiving opioids or with significant chronic disease (eg, respiratory compromise) (Ref). Avoid use in patients with a history of substance use, misuse of medications, or depression (Ref).

Alcohol withdrawal syndrome

Alcohol withdrawal syndrome (alternative agent):

Note : Withdrawal will progress at different rates in some patients; flexibility in dosing and duration is warranted (Ref). Regimens vary and depend on withdrawal history, degree of current withdrawal symptoms, blood alcohol concentration, and whether the patient is treated inpatient or in the ambulatory setting. Many facilities only treat alcohol withdrawal in the ambulatory setting if Clinical Institute Withdrawal Assessment for Alcohol, revised scale (CIWA-Ar) score is ≤15 and there is no history of withdrawal seizures or delirium tremens (Ref). Although longer-acting benzodiazepines are preferred in general, shorter-acting benzodiazepines, including oxazepam, may be preferable in patients with impaired liver function (Ref). The following are 2 suggested regimens.

Symptom-triggered regimen:

Note: Some experts recommend symptom-triggered regimen for patients with CIWA-Ar >15 (Ref).

Oral: 15 to 30 mg as needed per institution-specific protocol until appropriate sedation achieved; dose and frequency determined by withdrawal symptom severity using a validated severity assessment scale, such as the CIWA-Ar (Ref).

Fixed-dose regimen:

Note: Some experts recommend fixed-dose regimens for patients at risk for mild withdrawal (CIWA-Ar ≤15), particularly in an ambulatory setting where CIWA-Ar scores cannot be reliably administered. Hold doses for excessive sedation (Ref).

Day 1: Oral: 30 mg every 6 hours.

Day 2 and 3: Oral: 15 mg every 6 hours (Ref).

Breakthrough symptoms: Oral: May administer up to 5 additional as-needed 15 to 30 mg doses to be used over the 4-day treatment period for breakthrough symptoms (Ref).

Anxiety disorders

Anxiety disorders (adjunctive therapy or monotherapy) (alternative agent):

Note: Generally used short term for symptom relief until preferred therapy (eg, serotonin reuptake inhibitor) is effective (eg, 4 to 6 weeks, followed by tapering). Long-term, low-dose therapy (eg, 7.5 mg/day) may be considered in select patients when other treatments are ineffective or poorly tolerated (Ref). Use with caution in patients with comorbid posttraumatic stress disorder; benzodiazepines may cause cognitive changes (Ref).

Oral: Initial: 10 to 15 mg 3 times daily (Ref); although most patients will experience relief with this dose, may increase daily dose based on response and tolerability in increments of 15 to 30 mg every 2 to 3 days to a total daily dose of 30 to 120 mg/day in 3 to 4 divided doses (Ref). Usual dosage: 45 to 60 mg/day in divided doses (Ref).

Discontinuation of therapy: Unless safety concerns require a more rapid withdrawal, gradually taper to detect reemerging symptoms and minimize rebound and withdrawal symptoms (Ref).

Low or moderate dose, no concerns for benzodiazepine use disorder: Taper total daily dose by 20% to 25% every week based on response and tolerability (taper increments will be limited by available dosage forms) (Ref).

Extended or high-dose therapy, or suspected benzodiazepine use disorder: Taper total daily dose by approximately 25% every 1 to 2 weeks based on response, tolerability, and individual patient factors (taper increments will be limited by available dosage forms) (Ref). Reduce dose more rapidly in the beginning and slow the dose reduction as the taper progresses because earlier stages of withdrawal are easier to tolerate (Ref). The optimal duration and taper increment will vary; up to 6 months may be necessary for some patients on higher doses, and a taper rate of 50% every week may be tolerated in some patients (Ref). For benzodiazepines with half-lives significantly <24 hours, including oxazepam, consider substituting an equivalent dose of a long-acting benzodiazepine to allow for a more gradual reduction in drug serum concentrations (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling

Hemodialysis: Not dialyzable (0% to 5%) (Ref)

Dosing: Liver Impairment: Adult

There are no dosage adjustment provided in the manufacturer's labeling; however, pharmacokinetic studies have shown that hepatic dysfunction is not expected to significantly decrease clearance (Ref).

Dosing: Older Adult

Note: Avoid use, may be appropriate for anxiety disorders or ethanol withdrawal (Ref).

Anxiety disorders (adjunctive therapy or monotherapy): Oral: Initial: 10 mg 3 times daily. If necessary, increase cautiously to 15 mg 3 to 4 times daily.

Discontinuation of therapy: Refer to adult dosing.

Dosing: Pediatric

Children >12 years and Adolescents: Refer to adult dosing.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Hemodialysis: Not dialyzable (0% to 5%) (Ref)

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, pharmacokinetic studies have shown that hepatic dysfunction is not expected to significantly decrease clearance (Ref).

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.

Cardiovascular: Edema, hypotension, syncope

Central nervous system: Amnesia, ataxia, dizziness, drowsiness, drug dependence, dysarthria, euphoria, headache, lethargy, memory impairment, slurred speech, vertigo

Dermatologic: Maculopapular rash, morbilliform rash, urticaria

Endocrine & metabolic: Decreased libido, menstrual disease

Gastrointestinal: Nausea

Genitourinary: Urinary incontinence

Hematologic & oncologic: Hematologic disease, leukopenia

Hepatic: Jaundice

Hypersensitivity: Fixed drug eruption

Neuromuscular & skeletal: Hyporeflexia, tremor

Ophthalmic: Blurred vision, diplopia

Miscellaneous: Paradoxical central nervous system stimulation, paradoxical excitation

Contraindications

Hypersensitivity to oxazepam or any component of the formulation.

Canadian labeling: Additional contraindications (not in US labeling): Glaucoma (history of); myasthenia gravis; use in infants.

Warnings/Precautions

Concerns related to adverse effects:

• Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia (Nelson 1999).

• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).

• Hypotension: May cause hypotension (rare); use with caution in patients with cardiovascular or cerebrovascular disease, or in patients who would not tolerate transient decreases in blood pressure.

• Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients (Mancuso 2004).

• Sleep-related activities: Hazardous sleep-related activities such as sleep-driving, cooking and eating food, and making phone calls while asleep have been noted with benzodiazepines (Dolder 2008).

Disease-related concerns:

• Depression: Avoid use in patients with depression because of concerns about worsening mood symptoms, particularly if suicidal risk may be present, except for acute or emergency situations (eg, acute agitation, status epilepticus) (Craske 2022).

• Hepatic impairment: Use with caution in patients with hepatic impairment; however, oxazepam has been shown to be less affected by hepatic dysfunction due to its relative slow extraction by the liver and phase II metabolic pathway (glucuronidation) (Furlan 1999; Greenblatt 1981).

• Respiratory disease: Reduce dose or avoid use in patients with respiratory disease, including chronic obstructive pulmonary disease or sleep apnea. Benzodiazepines may cause significant respiratory depression.

Concurrent drug therapy issues:

• Concomitant use with opioids: [US Boxed warning]: Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.

Special populations:

• Older adult: Relative to other benzodiazepines, oxazepam possesses a short half-life and lacks an active metabolite which may be preferable in older adults if benzodiazepine use is required for anxiety (Flint 2005). Kinetics were not altered in patients of advanced age compared to younger patients, except in patients >80 years of age where an increased half-life was observed due to an increased volume of distribution and a decrease in unbound clearance. Older adult patients may be at an increased risk of death with use; risk has been found highest within the first 4 months of use in older adult dementia patients (Jennum 2015; Saarelainen 2018).

• Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury (Nelson 1999).

Other warnings/precautions:

• Abuse, misuse, and substance use disorder: [US Boxed warning]: The use of benzodiazepines, including oxazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Assess each patient's risk for abuse, misuse, and addiction prior to and throughout treatment; counsel patients at increased risk on proper use and monitoring for signs and symptoms of abuse, misuse, and substance use disorder. Institute early treatment or refer patients in whom substance use disorder is suspected. Limit dosages and durations to the minimum required.

• Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties; not indicated for use in the treatment of psychosis.

• Dependence and withdrawal reactions: [US Boxed warning]: The continued use of benzodiazepines, including oxazepam, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of oxazepam after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue oxazepam or reduce the dosage. Some patients may develop a protracted withdrawal syndrome lasting >12 months; may be difficult to differentiate withdrawal symptoms from reemergence or continuation of symptoms for which benzodiazepines were prescribed. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.

• Tolerance: Oxazepam is a short half-life benzodiazepine. Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance does not develop to the anxiolytic effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired effect.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 10 mg, 15 mg, 30 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (Oxazepam Oral)

10 mg (per each): $1.15

15 mg (per each): $1.45

30 mg (per each): $2.10

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 10 mg, 15 mg, 30 mg

Controlled Substance

C-IV

Administration: Pediatric

Oral: Administer without regard to meals.

Use: Labeled Indications

Alcohol withdrawal syndrome: Management of the symptoms associated with alcohol withdrawal, including tremor and anxiety.

Anxiety disorders: Treatment of anxiety disorders or short-term relief of the symptoms of anxiety, including anxiety associated with depression and anxiety, tension, agitation, and irritability in older patients.

Medication Safety Issues
Sound-alike/look-alike issues:

Oxazepam may be confused with oxcarbazepine, oxaprozin, quazepam

Serax may be confused with Eurax, Urex, ZyrTEC

Older Adult: High-Risk Medication:

Beers Criteria: Oxazepam is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to risk of abuse, misuse, physical dependence and addiction. In addition, older adults have increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use. However, benzodiazepines may be appropriate in the elderly when used for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine or ethanol withdrawal, severe generalized anxiety disorder, or periprocedural anesthesia (Beers Criteria [AGS 2023]).

International issues:

Murelax [Australia] may be confused with MiraLax brand name for polyethylene glycol 3350 [US]

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Acrivastine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Alcohol (Ethyl): CNS Depressants may increase CNS depressant effects of Alcohol (Ethyl). Risk C: Monitor

Alizapride: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Amisulpride (Oral): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

ARIPiprazole Lauroxil: May increase CNS depressant effects of Benzodiazepines. ARIPiprazole Lauroxil may increase hypotensive effects of Benzodiazepines. Specifically, the risk of orthostatic hypotension may be increased. Risk C: Monitor

ARIPiprazole: May increase CNS depressant effects of Benzodiazepines. ARIPiprazole may increase hypotensive effects of Benzodiazepines. Specifically, orthostatic hypotension may be increased. Risk C: Monitor

Articaine: May increase CNS depressant effects of CNS Depressants. Management: Consider reducing the dose of articaine if possible when used in patients who are also receiving CNS depressants. Monitor for excessive CNS depressant effects with any combined use. Risk D: Consider Therapy Modification

Azelastine (Nasal): May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Benperidol: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Beta-Acetyldigoxin: Benzodiazepines may increase serum concentration of Beta-Acetyldigoxin. Risk C: Monitor

Blonanserin: CNS Depressants may increase CNS depressant effects of Blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin. Risk D: Consider Therapy Modification

Brexanolone: CNS Depressants may increase CNS depressant effects of Brexanolone. Risk C: Monitor

Brimonidine (Topical): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Bromopride: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Bromperidol: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Buclizine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Buprenorphine: CNS Depressants may increase CNS depressant effects of Buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants. Risk D: Consider Therapy Modification

BusPIRone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Cannabinoid-Containing Products: CNS Depressants may increase CNS depressant effects of Cannabinoid-Containing Products. Risk C: Monitor

Certoparin: May increase serum concentration of Benzodiazepines. Risk C: Monitor

Cetirizine (Systemic): May increase CNS depressant effects of CNS Depressants. Management: Consider avoiding this combination if possible. If required, monitor for excessive sedation or CNS depression, limit the dose and duration of combination therapy, and consider CNS depressant dose reductions. Risk D: Consider Therapy Modification

Chloral Hydrate/Chloral Betaine: CNS Depressants may increase CNS depressant effects of Chloral Hydrate/Chloral Betaine. Management: Consider alternatives to the use of chloral hydrate or chloral betaine and additional CNS depressants. If combined, consider a dose reduction of either agent and monitor closely for enhanced CNS depressive effects. Risk D: Consider Therapy Modification

Chlormethiazole: May increase CNS depressant effects of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used. Risk D: Consider Therapy Modification

Chlorphenesin Carbamate: May increase adverse/toxic effects of CNS Depressants. Risk C: Monitor

CloZAPine: Benzodiazepines may increase adverse/toxic effects of CloZAPine. Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression, hypotension, and other toxicities if these agents are combined. Risk D: Consider Therapy Modification

CNS Depressants: May increase adverse/toxic effects of CNS Depressants. Risk C: Monitor

Corticosteroids (Orally Inhaled): Benzodiazepines may increase adverse/toxic effects of Corticosteroids (Orally Inhaled). Specifically, the risk of pneumonia may be increased. Risk C: Monitor

Dantrolene: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Daridorexant: May increase CNS depressant effects of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended. Risk D: Consider Therapy Modification

DexmedeTOMIDine: CNS Depressants may increase CNS depressant effects of DexmedeTOMIDine. Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression. Risk D: Consider Therapy Modification

Difelikefalin: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Difenoxin: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Dihydralazine: CNS Depressants may increase hypotensive effects of Dihydralazine. Risk C: Monitor

Dimethindene (Topical): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Dothiepin: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Doxylamine: CNS Depressants may increase CNS depressant effects of Doxylamine. Risk C: Monitor

DroPERidol: May increase CNS depressant effects of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use. Risk D: Consider Therapy Modification

Emedastine (Systemic): May increase CNS depressant effects of CNS Depressants. Management: Consider avoiding this combination if possible. If required, monitor for excessive sedation or CNS depression, limit the dose and duration of combination therapy, and consider CNS depressant dose reductions. Risk C: Monitor

Entacapone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Esketamine (Nasal): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Flunarizine: CNS Depressants may increase CNS depressant effects of Flunarizine. Risk X: Avoid

Flunitrazepam: CNS Depressants may increase CNS depressant effects of Flunitrazepam. Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available. Risk D: Consider Therapy Modification

HydrOXYzine: May increase CNS depressant effects of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant. Risk D: Consider Therapy Modification

Ilaprazole: May increase serum concentration of Benzodiazepines. Risk C: Monitor

Ixabepilone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Kava Kava: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Ketotifen (Systemic): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Kratom: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Lemborexant: May increase CNS depressant effects of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary. Risk D: Consider Therapy Modification

Levocetirizine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Lisuride: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Lofepramine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Lofexidine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Loxapine: CNS Depressants may increase CNS depressant effects of Loxapine. Management: Consider reducing the dose of CNS depressants administered concomitantly with loxapine due to an increased risk of respiratory depression, sedation, hypotension, and syncope. Risk D: Consider Therapy Modification

Magnesium Sulfate: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Melatonin: May increase sedative effects of Benzodiazepines. Risk C: Monitor

Melitracen [INT]: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Mequitazine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Metergoline: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Methadone: Benzodiazepines may increase CNS depressant effects of Methadone. Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution. Risk D: Consider Therapy Modification

Methotrimeprazine: CNS Depressants may increase CNS depressant effects of Methotrimeprazine. Methotrimeprazine may increase CNS depressant effects of CNS Depressants. Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression. Risk D: Consider Therapy Modification

Methoxyflurane: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Metoclopramide: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

MetyroSINE: CNS Depressants may increase sedative effects of MetyroSINE. Risk C: Monitor

Minocycline (Systemic): May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Moxonidine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Nabilone: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Nalfurafine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Noscapine: CNS Depressants may increase adverse/toxic effects of Noscapine. Risk X: Avoid

OLANZapine: Benzodiazepines may increase adverse/toxic effects of OLANZapine. Management: Monitor closely for hypotension, respiratory or central nervous system depression, and bradycardia if olanzapine is combined with benzodiazepines. Use of parenteral benzodiazepines with IM olanzapine is not recommended. Risk C: Monitor

Olopatadine (Nasal): May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Opicapone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Opioid Agonists: CNS Depressants may increase CNS depressant effects of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider Therapy Modification

Opipramol: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Orphenadrine: CNS Depressants may increase CNS depressant effects of Orphenadrine. Risk X: Avoid

Oxomemazine: May increase CNS depressant effects of CNS Depressants. Risk X: Avoid

Oxybate Salt Products: Benzodiazepines may increase CNS depressant effects of Oxybate Salt Products. Risk X: Avoid

OxyCODONE: CNS Depressants may increase CNS depressant effects of OxyCODONE. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug. Risk D: Consider Therapy Modification

Paliperidone: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Paraldehyde: CNS Depressants may increase CNS depressant effects of Paraldehyde. Risk X: Avoid

Perampanel: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Periciazine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Pipamperone: May increase adverse/toxic effects of CNS Depressants. Risk C: Monitor

Piribedil: CNS Depressants may increase CNS depressant effects of Piribedil. Risk C: Monitor

Pizotifen: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Pramipexole: CNS Depressants may increase sedative effects of Pramipexole. Risk C: Monitor

Procarbazine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Rilmenidine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Ropeginterferon Alfa-2b: CNS Depressants may increase adverse/toxic effects of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased. Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania). Risk D: Consider Therapy Modification

ROPINIRole: CNS Depressants may increase sedative effects of ROPINIRole. Risk C: Monitor

Rotigotine: CNS Depressants may increase sedative effects of Rotigotine. Risk C: Monitor

Suvorexant: CNS Depressants may increase CNS depressant effects of Suvorexant. Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Risk D: Consider Therapy Modification

Teduglutide: May increase serum concentration of Benzodiazepines. Risk C: Monitor

Thalidomide: CNS Depressants may increase CNS depressant effects of Thalidomide. Risk X: Avoid

Theophylline Derivatives: May decrease therapeutic effects of Benzodiazepines. Risk C: Monitor

Trimeprazine: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Valerian: May increase CNS depressant effects of CNS Depressants. Risk C: Monitor

Yohimbine: May decrease therapeutic effects of Antianxiety Agents. Risk C: Monitor

Zolpidem: CNS Depressants may increase CNS depressant effects of Zolpidem. Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol. Risk D: Consider Therapy Modification

Zuranolone: May increase CNS depressant effects of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects. Risk D: Consider Therapy Modification

Reproductive Considerations

Evaluate pregnancy status prior to use. Pregnancy testing is recommended before treating acute alcohol withdrawal symptoms; however, treatment should not be delayed in symptomatic patients if pregnancy status is unknown (ASAM 2020).

Oxazepam is not a first-line medication to treat anxiety disorders prior to conception in patients who are treatment naïve or who do not have a history of effective treatment with a specific medication. Patients effectively treated may continue their current medication when planning a pregnancy unless contraindications exist. Management of mental health conditions in patients who could become pregnant should be based on a shared decision-making process that considers the possibility of pregnancy during treatment (ACOG 2023; BAP [McAllister-Williams 2017]).

Pregnancy Considerations

Oxazepam crosses the placenta and can be measured in newborn serum at delivery (Jørgensen 1988; Kangas 1980; Tomson 1978; Tomson 1979).

In utero exposure to benzodiazepines has the potential to cause harm to the fetus. Teratogenic effects have been observed in some studies; however, a clear association has not been reported and additional data are needed (Bellantuono 2013; Chuang 2024; Freeman 2018; Grigoriadis 2019; Tinker 2019; Wu 2024). Exposure to a benzodiazepine late in pregnancy may cause neonatal sedation (hypotonia, lethargy, respiratory depression) and/or symptoms of neonatal withdrawal (feeding difficulties, hyperreflexia, inconsolable crying, irritability, restlessness, tremors). Monitor newborns exposed to oxazepam in utero for adverse events. Data related to long-term effects on neurodevelopment following maternal use of benzodiazepines are inconclusive (Andrade 2024; Radojčić 2017; Sundbakk 2024; Wang 2022).

Benzodiazepines are one of the preferred options for treating pregnant patients with alcohol withdrawal. Inpatient treatment is recommended during pregnancy. Agents with a shorter onset and duration of action should be used if near delivery. Monitor newborns for fetal alcohol spectrum disorder, sedative withdrawal, and intoxication (ASAM 2020).

Untreated and undertreated mental health conditions are associated with adverse pregnancy outcomes. Anxiety disorders during pregnancy are associated with low birth weight, preterm birth, and adverse behavioral outcomes in the offspring. Discontinuing effective medications during pregnancy increases the risk of relapse. Management should be made as part of a shared decision-making process. Agents other than oxazepam may be preferred when treatment for anxiety is initiated for the first time during pregnancy. The use of benzodiazepines for the treatment of perinatal anxiety should be avoided or used sparingly until preferred therapy is initiated and effective, or when preferred therapy is not effective; oxazepam may be a preferred benzodiazepine in patients with preeclampsia. When medications are used, the lowest effective dose of a single agent is recommended. Optimize dosing prior to changing a medication or adding additional agents whenever possible. Monthly monitoring for symptom improvement with a validated screening tool during pregnancy is recommended. Manage side effects as needed (ACOG 2023).

Data collection to monitor pregnancy and infant outcomes following exposure to oxazepam is ongoing. Health care providers are encouraged to enroll patients exposed to oxazepam during pregnancy in the National Pregnancy Registry for Psychiatric Medications (1-866-961-2388).

Breastfeeding Considerations

Oxazepam is present in breast milk.

Data related to the presence of oxazepam in breast milk are available from case reports:

• Oxazepam 10 mg was administered 3 times a day for 3 days to a lactating patient 7 months postpartum. Breast milk was sampled prior to the morning and evening doses. Oxazepam concentrations in breast milk were between 24 and 30 mcg/L over the study period and averaged 10% to 33% of the maternal plasma concentrations (Wretlind 1987).

• Oxazepam was present in the breast milk of a patient undergoing detoxification from long-term ingestion of multiple benzodiazepines. At presentation, she was 12 months postpartum, taking oxazepam 30 mg/day and diazepam 80 mg/day. On day 14 of the withdrawal schedule, oxazepam breast milk concentrations were 30 mcg/L and decreased to not detectable by day 39. The infant was weaned from 6 to 3 to 4 feedings per day and did not show signs of benzodiazepine intoxication (Dusci 1990).

Drowsiness, lethargy, or weight loss in breastfeeding infants have been observed in case reports following maternal use of some benzodiazepines (Iqbal 2002).

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. A benzodiazepine with a short half-life (such oxazepam) can be considered for the treatment of anxiety in patients who are breastfeeding. Avoid benzodiazepines with long half-life or multiple active metabolites (Eleftheriou 2024). Monitor infants exposed to oxazepam via breast milk for feeding problems, respiratory depression, and poor weight gain.

Monitoring Parameters

Respiratory and cardiovascular status (as clinically indicated); CBC (periodic); liver function tests (periodic)

Mechanism of Action

Short-acting benzodiazepine (Griffin 2013). Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors (Vinkers 2012).

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Slowly absorbed from the GI tract (Greenblatt 1981).

Duration of action: Classified as a short-acting benzodiazepine; classification based on benzodiazepines with half-life of 1 to 12 hours (Griffin 2013).

Distribution: Vd: 0.6 to 2 L/kg (Greenblatt 1981).

Protein binding: 96% to 98% (Greenblatt 1981).

Metabolism: Hepatic glucuronide conjugation to produce a single, major inactive metabolite (benzophenone) (Greenblatt 1981).

Half-life elimination: ~8 hours (range: 6 to 11 hours).

Time to peak, serum: ~3 hours.

Excretion: Urine (as inactive glucuronide conjugate).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: In patients with severe renal insufficiency, the elimination half-life of oxazepam was prolonged to a mean of 48 hours (range: 24 to 91); however, clearance of total drug was relatively normal suggesting that a large increase in volume of distribution accounts for the prolongation in half-life (Greenblatt 1981).

Older adult: A statistically significant increase in elimination half-life in patients >80 years of age has been reported, due to a 30% increase in volume of distribution and a 50% reduction in unbound clearance of oxazepam.

Sex: A small but statistically significant prolongation of half-life elimination (9.7 hours versus 7.8 hours) and reduction of total clearance (0.82 mL/minute/kg versus 1.15 mL/minute/kg) has been reported in females in comparison to males, respectively (Greenblatt 1981).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Adumbran | Serepax;
  • (AT) Austria: Adumbran | Anxiolit | Praxiten;
  • (AU) Australia: Alepam | Apo oxazepam | Murelax | Serepax;
  • (BD) Bangladesh: Anoxa;
  • (BE) Belgium: Oxazepam efeka | Oxazepam eurogenerics | Oxazepam teva generics belgium | Seresta | Tranquo;
  • (BG) Bulgaria: Tazepam;
  • (BR) Brazil: Ansiepax;
  • (CH) Switzerland: Anxiolit | Seresta | Seresta expidet;
  • (CI) Côte d'Ivoire: Seresta;
  • (CL) Chile: Serepax;
  • (CN) China: You fei;
  • (CZ) Czech Republic: Apo oxazepam;
  • (DE) Germany: Adumbran | Azutranquil | Durazepam | Meproxam | Mirfudorm | Noctazepam | Oxa | Oxa 1a pharma | Oxahexal | Oxazepam 1a pharma | Oxazepam al | Oxazepam hexal | Oxazepam Ratiopharm | Oxazepam Sandoz | Praxiten | Sigacalm | Uskan;
  • (DK) Denmark: Oxapax;
  • (DO) Dominican Republic: Limbial;
  • (EE) Estonia: Nozepam | Oxazepam alpharma | Oxazepam Ratiopharm | Tazepam | Uskan;
  • (EG) Egypt: Comedormir | Oxazin | Oxepam | Seropar;
  • (ES) Spain: Adumbran;
  • (FI) Finland: Alopam | Opamox | Oxamin | Oxepam;
  • (FR) France: Seresta;
  • (GB) United Kingdom: Abboxapam | Lederpam | Oxanid | Oxazepam aps | Oxazepam berk | Oxazepam cox | Oxazepam dc | Oxazepam kent | Oxazepam steinhard | Serenid d | Serenid forte;
  • (HR) Croatia: Oksazepam | Oksazepam Belupo | Praxiten;
  • (IE) Ireland: Alepam;
  • (IL) Israel: Vaben;
  • (IN) India: Anxozap | Azenap | Oxiuse | Serepax | Zaxpam;
  • (IT) Italy: Limbial | Oxapam | Quilibrex | Serpax;
  • (JP) Japan: Hilong | Propax | Wakazepam;
  • (LT) Lithuania: Apo oxazepam | Nozepam | Oxazepam bp | Tazepam;
  • (LU) Luxembourg: Seresta | Tranquo;
  • (LV) Latvia: Apo oxazepam | Nozepam | Tazepam;
  • (MY) Malaysia: Tazepam;
  • (NL) Netherlands: Oxazepam A | Oxazepam accord | Oxazepam Gf | Oxazepam Sandoz | Seresta;
  • (NO) Norway: Alopam | Delipam | Oxapax | Serepax | Sobril;
  • (NZ) New Zealand: Benzotran | Ox-pam | Serepax;
  • (PR) Puerto Rico: Serax;
  • (PT) Portugal: Serenal;
  • (RU) Russian Federation: Nozepam | Tazepam;
  • (SE) Sweden: Alopam | Delipam | Oxascand | Serepax | Sobril;
  • (SI) Slovenia: Adumbran | Oksazepam | Praxiten;
  • (SR) Suriname: Apo oxazepam;
  • (TH) Thailand: Serax;
  • (TN) Tunisia: Seresta;
  • (TR) Turkey: Serepax;
  • (TW) Taiwan: Alepam | Alepan | Elinin | Isodin | Oxapam | Oxaze | Psiquiwas | Selars;
  • (UA) Ukraine: Nozepam | Tazepam;
  • (UY) Uruguay: Serefar | Silenpax;
  • (ZA) South Africa: Medopam | Noripam | Purata | Rolab-oxazepam | Serepax;
  • (ZM) Zambia: Purata
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. American College of Obstetricians and Gynecologists (ACOG). Treatment and management of mental health conditions during pregnancy and postpartum: ACOG clinical practice guideline no. 5. Obstet Gynecol. 2023;141(6):1262-1288. doi:10.1097/AOG.0000000000005202 [PubMed 37486661]
  3. American Society of Addiction Medicine (ASAM). The ASAM clinical practice guideline on alcohol withdrawal management. J Addict Med. 2020;14(3S)(suppl 1):1-72. doi:10.1097/ADM.0000000000000668 [PubMed 32511109]
  4. Andrade C, Varadharajan N, Bascarane S, Menon V. Gestational exposure to benzodiazepines or z-hypnotics and neurodevelopmental disorders in offspring: systematic review and meta-analysis. Acta Psychiatr Scand. 2024;150(2):65-77. doi:10.1111/acps.13696 [PubMed 38751163]
  5. Ansseau M, Papart P, Gérard MA, von Frenckell R, Franck G. Controlled comparison of buspirone and oxazepam in generalized anxiety. Neuropsychobiology. 1990-1991;24(2):74-78. doi:10.1159/000119464 [PubMed 2134114]
  6. Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. World J Biol Psychiatry. 2023;24(2):79-117. doi:10.1080/15622975.2022.2086295 [PubMed 35900161]
  7. Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry. 2013;35(1):3-8. doi:10.1016/j.genhosppsych.2012.09.003 [PubMed 23044244]
  8. Bergman U, Rosa FW, Baum C, et al. Effects of exposure to benzodiazepine during fetal life. Lancet. 1992;340(8821):694-696. [PubMed 1355799]
  9. Chuang HM, Meng LC, Lin CW, et al. Concomitant use of antidepressants and benzodiazepines during pregnancy and associated risk of congenital malformations: a population-based cohort study in Taiwan. Lancet Psychiatry. 2024;11(8):601-610. doi:10.1016/S2215-0366(24)00176-7 [PubMed 38968942]
  10. Craske M, Bystritsky A. Generalized anxiety disorder in adults: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 19, 2022.
  11. Currow DC, Agar MR. Benzodiazepine prescribing in people with chronic obstructive pulmonary disease: clinical considerations. Drugs Aging. 2020;37(4):263-270. doi:10.1007/s40266-020-00756-z [PubMed 32107742]
  12. Daeppen JB, Gache P, Landry U, et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med. 2002;162(10):1117-1121. doi:10.1001/archinte.162.10.1117 [PubMed 12020181]
  13. Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. CNS Drugs. 2008;22(12):1021-1036. doi:10.2165/0023210-200822120-00005 [PubMed 18998740]
  14. Dusci LJ, Good SM, Hall RW, Ilett KF. Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. Br J Clin Pharmacol. 1990;29(1):123-126. doi:10.1111/j.1365-2125.1990.tb03612.x [PubMed 2105100]
  15. Eleftheriou G, Zandonella Callegher R, Butera R, et al. Consensus panel recommendations for the pharmacological management of breastfeeding women with postpartum depression. Int J Environ Res Public Health. 2024;21(5):551. doi:10.3390/ijerph21050551 [PubMed 38791766]
  16. Flint AJ. Generalised Anxiety Disorder in Elderly Patients: Epidemiology, Diagnosis and Treatment Options. Drugs Aging. 2005;22(2):101-114. [PubMed 15733018]
  17. Freeman MP, Góez-Mogollón L, McInerney KA, et al. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: results from a prospective registry of women with psychiatric disorders. Gen Hosp Psychiatry. 2018;53:73-79. doi:10.1016/j.genhosppsych.2018.05.010 [PubMed 29958100]
  18. Furlan V, Demirdjian S, Bourdon O, et al. Glucuronidation of Drugs by Hepatic Microsomes Derived from Health and Cirrhotic Human Livers. J Pharmacol Exp Ther. 1999;289(2):1169-1175. [PubMed 10215701]
  19. Greenblatt DJ. Clinical Pharmacokinetics of Oxazepam and Lorazepam. Clin Pharmacokinet. 1981;6(2):89-105. [PubMed 6111408]
  20. Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13(2):214-223. [PubMed 23789008]
  21. Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis. J Clin Psychiatry. 2019;80(4):18r12412. doi:10.4088/JCP.18r12412 [PubMed 31294935]
  22. Hoffman RS, Weinhouse GL. Management of moderate and severe alcohol withdrawal syndromes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 14, 2023.
  23. Iqbal MM, Sobhan T, Ryals T, et al. Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant. Psychiatr Serv. 2002;53(1):39-49. [PubMed 11773648]
  24. Jennum P, Baandrup L, Ibsen R, et al. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study. Eur Neuropsychopharmacol. 2015;25(11):1906-1913. doi:10.1016/j.euroneuro.2015.08.014 [PubMed 26342397]
  25. Jørgensen NP, Thurmann-Nielsen E, Walstad RA. Pharmacokinetics and distribution of diazepam and oxazepam in early pregnancy. Acta Obstet Gynecol Scand. 1988;67(6):493-497. doi:10.3109/00016348809029859 [PubMed 3239381]
  26. Kangas L, Erkkola R, Kanto J, et al. Transfer of Free and Conjugated Oxazepam Across the Human Placenta. Eur J Clin Pharmacol. 1980;17(4):301-304. [PubMed 7398730]
  27. Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1 [PubMed 25081580]
  28. Lader M. Benzodiazepines revisited--will we ever learn? Addiction. 2011;106(12):2086-2109. doi:10.1111/j.1360-0443.2011.03563.x [PubMed 21714826]
  29. Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy. 2004;24(9):1177-1185. [PubMed 15460178]
  30. McAllister-Williams RH, Baldwin DS, Cantwell R, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017;31(5):519-552. doi:10.1177/0269881117699361 [PubMed 28440103]
  31. Mokhlesi B, Leikin JB, Murray P, et al, “Adult Toxicology in Critical Care: Part II: Specific Poisonings,” Chest, 2003, 123(3):897-922. [PubMed 12628894]
  32. Moore TA. Ambulatory detoxification in alcohol use disorder and opioid use disorder. Ment Health Clin. 2020;10(6):307-316. doi:10.9740/mhc.2020.11.307 [PubMed 33224688]
  33. Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound, and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol. 1999;6(2):69-83. [PubMed 10519733]
  34. Oxazepam capsules [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; August 2023.
  35. Oxpam [product monograph]. Saint-Léonard, Quebec, Canada: Biomed Pharma; May 2022.
  36. Park TW. Benzodiazepine use disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 12, 2022.
  37. Radojčić MR, El Marroun H, Miljković B, et al. Prenatal exposure to anxiolytic and hypnotic medication in relation to behavioral problems in childhood: a population-based cohort study. Neurotoxicol Teratol. 2017;61:58-65. doi:10.1016/j.ntt.2017.02.005 [PubMed 28259732]
  38. Refer to manufacturer’s labeling.
  39. Rimón R, Kultalahti ER, Kalli A, et al. Alprazolam and oxazepam in the treatment of anxious out-patients with depressive symptoms: a double-blind multicenter study. Pharmacopsychiatry. 1991;24(3):81-84. doi:10.1055/s-2007-1014444 [PubMed 1891485]
  40. Saarelainen L, Tolppanen AM, Koponen M, et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study. Int J Geriatr Psychiatry. 2018;33(4):583-590. doi:10.1002/gps.4821 [PubMed 29143367]
  41. Soyka M, Kranzler HR, Hesselbrock V, Kasper S, Mutschler J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Substance Use Disorders. Guidelines for biological treatment of substance use and related disorders, part 1: alcoholism, first revision. World J Biol Psychiatry. 2017;18(2):86-119. doi:10.1080/15622975.2016.1246752 [PubMed 28006997]
  42. Sundbakk LM, Wood M, Gran JM, Nordeng H. Prenatal exposure to benzodiazepine and z-hypnotics and fifth-grade scholastic skills - emulating target trials using data from the Norwegian Mother, Father and Child Cohort Study. Am J Epidemiol. 2024:kwae159. doi:10.1093/aje/kwae159 [PubMed 38944758]
  43. Tinker SC, Reefhuis J, Bitsko RH, et al; National Birth Defects Prevention Study. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. Birth Defects Res. 2019;111(10):613-620. doi:10.1002/bdr2.1497 [PubMed 30891943]
  44. Tomson G, Lunell NO, Sundwall A, Rane A. Pharmacokinetics of oxazepam given during labour. Acta Psychiatr Scand Suppl. 1978;(274):75-81. doi:10.1111/j.1600-0447.1978.tb02389.x [PubMed 282778]
  45. Tomson G, Lunell NO, Sundwall A, Rane A. Placental passage of oxazepam and its metabolism in mother and newborn. Clin Pharmacol Ther. 1979;25(1):74-81. doi:10.1002/cpt197925174 [PubMed 758245]
  46. US Department of Veterans Affairs/US Department of Defense. VA/DoD clinical practice guideline for management of posttraumatic stress disorder and acute stress disorder. https://www.healthquality.va.gov/guidelines/MH/ptsd/VA-DoD-CPG-PTSD-Full-CPG.pdf. Published 2023. Accessed November 27, 2023.
  47. US Department of Veterans Affairs/US Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf. Published August 2021. Accessed May 12, 2022.
  48. Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective gaba(a) receptor modulators? Adv Pharmacol Sci. 2012;2012:1-19. [PubMed 22536226]
  49. Wang X, Zhang T, Ekheden I, et al. Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: a systematic review. Neurosci Biobehav Rev. 2022;137:104647. doi:10.1016/j.neubiorev.2022.104647 [PubMed 35367514]
  50. Wretlind M. Excretion of oxazepam in breast milk. Eur J Clin Pharmacol. 1987;33(2):209-210. doi:10.1007/BF00544570 [PubMed 3691611]
  51. Wu HN, Liang Y, Li LL, Jiang HY, Xu LL. The safety of benzodiazepines and related drugs during pregnancy: an updated meta-analysis of cohort studies. Arch Gynecol Obstet. 2024;310(1):45-54. doi:10.1007/s00404-024-07557-4 [PubMed 38806942]
Topic 9726 Version 328.0